Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.
Robarts Research Institute, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.
Trends Pharmacol Sci. 2019 Mar;40(3):212-225. doi: 10.1016/j.tips.2019.01.004. Epub 2019 Feb 4.
Interest in lipoprotein (a) [Lp(a)] has exploded over the past decade with the emergence of genetic and epidemiological studies pinpointing elevated levels of this unique lipoprotein as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD). This review summarizes the most recent discoveries regarding therapeutic approaches to lower Lp(a) and presents these findings in the context of an emerging, although far from complete, understanding of the biosynthesis and catabolism of Lp(a). Application of Lp(a)-specific lowering agents to outcome trials will be the key to opening this new frontier in the battle against CVD.
在过去的十年中，随着遗传和流行病学研究的出现，人们对脂蛋白 (a) [Lp(a)] 的兴趣大增，这些研究指出这种独特脂蛋白水平升高是动脉粥样硬化性心血管疾病 (ASCVD) 和钙化性主动脉瓣疾病 (CAVD) 的因果风险因素。这篇综述总结了最近关于降低 Lp(a) 的治疗方法的发现，并在 Lp(a) 的生物合成和分解代谢的新兴但远非完整的理解的背景下呈现了这些发现。将 Lp(a) 特异性降低剂应用于结局试验将是开拓 CVD 治疗新领域的关键。
